Jaguar Health Files 8-K with Financials and Exhibits

TL;DR

Jaguar Health dropped an 8-K, mostly financials & exhibits. Nothing earth-shattering in this snippet.

AI Summary

On April 30, 2025, Jaguar Health, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific new material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates that Jaguar Health is providing updated financial information and exhibits to the SEC, which is standard for public companies and may contain details relevant to investors.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for financial statements and exhibits, not indicating any immediate new risks or significant events.

Key Players & Entities

• Jaguar Health, Inc. (company) — Registrant
• April 30, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-36714 (identifier) — Commission File Number
• 200 Pine Street Suite 400 (address) — Principal Executive Offices
• San Francisco, California (location) — Principal Executive Offices City and State
• 94104 (zip_code) — Principal Executive Offices Zip Code
• (415) 371-8300 (phone_number) — Registrant's Telephone Number

FAQ

From the Filing

0001193125-25-105825.txt : 20250430 0001193125-25-105825.hdr.sgml : 20250430 20250430081522 ACCESSION NUMBER: 0001193125-25-105825 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250430 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250430 DATE AS OF CHANGE: 20250430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 25891137 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 d935544d8k.htm 8-K 8-K false 0001585608 0001585608 2025-04-30 2025-04-30     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-36714   46-2956775 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.) 200 Pine Street Suite 400     San Francisco , California     94104 (Address of Principal Executive Offices)     (Zip Code) Registrant’s Telephone Number, Including Area Code:  (415)   371-8300   (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 7.01 Regulation FD Disclosure. On April 30, 2025, Jaguar Health, Inc. (the “Company”) issued a press release announcing initial proof-of-concept results related to crofelemer. The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exc